Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia

Platelets

Volumn 23, Issue 5, 2012, Pages 336-343

  Arellano Rodrigo, Eduardo ^a   Alvarez Larrán, Alberto ^a   Reverter, Juan Carlos ^a   Villamor, Neus ^a   Jou, Josep Maria ^a   Cervantes, Francisco ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ADVIA 120 system; Automated analysis; Essential thrombocythemia; JAK2 V617F mutation; Neutrophil activation; Platelet activation

Indexed keywords

CD11B ANTIGEN; JANUS KINASE 2; MYELOPEROXIDASE; PADGEM PROTEIN;

ADULT; AGED; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; HUMANS; JANUS KINASE 2; MIDDLE AGED; NEUTROPHIL ACTIVATION; NEUTROPHILS; PLATELET ACTIVATION; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

MOROCCAN PEPPER VIRUS;

EID: 84863713286     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.630112     Document Type: Article

References (34)

1. Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006;17:528-544.
2. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-175.
3. Cervantes F, Arellano-Rodrigo E, Alvarez-Larran A. Blood cell activation in the myeloproliferative neoplasms. Haematologica 2009;94:1484-1488.
4. Macey M, Azam U, McCarthy D, Webb L, Chapman ES, Okrongly D, Zelmanovic D, Newland A. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 Haematology System. Clin Chem 2002;48:891-899.
5. Ross DW, Bentley SA. Evaluation of an automated hematology system (Technicon H-1). Arch Pathol Lab Med 1986;110:803-808.
6. Kunicka JE, Fischer G, Murphy J, Zelmanovic D. Improved platelet counting using two-dimensional laser light scatter. Am J Clin Pathol 2000;114:283-289.
7. Macey MG, Carty E, Webb L, Chapman ES, Zelmanovic D, Okrongly D, Rampton DS, Newland AC. Use of mean platelet component to measure platelet activation on the ADVIA 120 Haematology System. Cytometry 1999;38:250-255.
8. Giacomini A, Legovini P, Antico F, Valverde S, Salvadego MM, Manoni F, Gessoni G. Assessment of in vitro platelet activation by ADVIA 120 platelet parameters. Lab Hematol 2003;9:132-137.
9. Diaz-Ricart M, Brunso L, Pino M, Navalon F, Jou JM, Heras M, White JG, Escolar G. Preanalytical treatment of EDTA-anticoagulated blood to ensure stabilization of the mean platelet volume and component measured with the ADVIA counters. Thromb Res 2010;126:e30-e35.
10. Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Gisslinger H. Essential thrombocythemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Thiele J, and Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. pp 48-50.
11. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 2009;84:102-108.
12. Bath PMW. The routine measurement of platelet size using sodium citrate alone as the anticoagulant. Thromb Haemost 1993;70:687-690.
13. Leckie MJ, Gomma AH, Purcell IF, Nyawo B, Dewar A, Okrongly D, Burman JF, Hooper J, Barnes PJ, Clague JR, et al. Automated quantitation of peripheral blood neutrophil activation in patients with myocardial ischaemia. Int J Cardiol 2004;95:307-313.
14. Kramer MS, Feinstein AR. Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 1981;29:111-123.
15. Landis RJ, Koch GG. The measurement of observer agreement data. Biometrics 1977;33:159-174.
16. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
17. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266.
18. Froom P, Quitt M, Aghai E. The mean leukocyte myeloperoxidase index in hematological patients. Am J Clin Pathol 1989;92:791-793.
19. Gulley ML, Bentley SA, Ross DW. Neutrophil myeloperoxidase measurement uncovers masked megaloblastic anemia. Blood 1990;76:1004-1006.
20. Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A, Gehling UM, Brümmer J, Rudolph V, Münzel T, Heitzer T, Meinertz T, Baldus S. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 2005;102:431-436.
21. Small BM, Bettigole RE. Diagnosis of myeloproliferative disease by analysis of the platelet volume distribution. Am J Clin Pathol 1981;76:685-691.
22. Sehayek E, Ben-Yosef N, Modan M, Chetrit A, Meytes D. Platelet parameters and aggregation in essential and reactive thrombocytosis. Am J Clin Pathol 1988;90:431-436.
23. Raman BKS, van Slyck EJ, Riddle J, Sawdyk MA, Abraham JP, Saeed SM. Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis. Am J Clin Pathol 1989;91:647-655.
24. Song YH, Park SH, Kim JE, Ahn JY, Seo YH, Park PH, Kim KH. Evaluation of platelet indices for differential diagnosis of thrombocytosis by ADVIA 120. Korean J Lab Med 2009;29:505-509.
25. Ahnadi CE, Chapman ES, Lépine M, Okrongly D, Pujol- Moix N, Hernandez A, Boughrassa F, Grant AM. Assessment of platelet activation in several different anticoagulants by the ADVIA 120 Hematology System, fluorescence flow cytometry, and electron microscopy. Thromb Haemost 2003;90:940-948.
26. Holme S, Murphy S. Studies of the platelet density abnormality in myeloproliferative disorders. J Lab Clin Med 1984;103:373-383.
27. Järemo P. Platelet density in essential thrombocythemia and polycythemia vera. Platelets 1999;10:61-63.
28. Milovanovic M, Lotfi K, Lindahl T, Hallert C, Järemo P. Platelet density distribution in essential thrombocythemia. Pathophysiol Haemost Thromb 2010;37:35-42.
29. Muth M, Büsche G, Bock O, Hussein K, Kreipe H. Aberrant proplatelet formation in chronic myeloproliferative neoplasms. Leuk Res 2010;34:1424-1429.
30. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002;99:1602-1609.
31. Chapman ES, Sorette M, Hetherington E, Zelmanovic D, Kling G, Dugailliez J, Pujol-Moix N, Okrongly D. A rapid, automated flow cytometric method to measure activated degranulated platelets by density determination. Thromb Haemost 2003;89:1004-1015.
32. Ahnadi CE, Boughrassa FF, Chapman-Montgomery ES, Poisson V, Gervais A, Okrongly D, Grant AM. Comparison of two methods to assess variability of platelet response to antiplatelet therapies in patients with acute coronary syndrome undergoing angioplasty. Thromb Haemost 2004;92:1207-1213.
33. Lambert JR, Gale RE, Linch DC. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia. Br J Haematol 2009;145:128-130.
34. Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech 2011;4:311-317.